These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31494468)

  • 21. Synthesis and Anticancer Cytotoxicity of Azaaurones Overcoming Multidrug Resistance.
    Tóth S; Szepesi Á; Tran-Nguyen VK; Sarkadi B; Német K; Falson P; Di Pietro A; Szakács G; Boumendjel A
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32050702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells.
    Shekari F; Sadeghpour H; Javidnia K; Saso L; Nazari F; Firuzi O; Miri R
    Eur J Pharmacol; 2015 Jan; 746():233-44. PubMed ID: 25445037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
    Gao M; Xu Y; Qiu L
    J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells.
    Lopes-Rodrigues V; Oliveira A; Correia-da-Silva M; Pinto M; Lima RT; Sousa E; Vasconcelos MH
    Bioorg Med Chem; 2017 Jan; 25(2):581-596. PubMed ID: 27908756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An insight into the structure of 5-spiro aromatic derivatives of imidazolidine-2,4-dione, a new group of very potent inhibitors of tumor multidrug resistance in T-lymphoma cells.
    Żesławska E; Kucwaj-Brysz K; Kincses A; Spengler G; Szymańska E; Czopek A; Marć MA; Kaczor A; Nitek W; Domínguez-Álvarez E; Latacz G; Kieć-Kononowicz K; Handzlik J
    Bioorg Chem; 2021 Apr; 109():104735. PubMed ID: 33640632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1).
    Schmitt SM; Stefan K; Wiese M
    J Med Chem; 2016 Apr; 59(7):3018-33. PubMed ID: 26943020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. O
    Li Q; Zou P; Sun J; Chen L
    Eur J Med Chem; 2018 Jan; 143():732-744. PubMed ID: 29220794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein.
    Fruttero R; Crosetti M; Chegaev K; Guglielmo S; Gasco A; Berardi F; Niso M; Perrone R; Panaro MA; Colabufo NA
    J Med Chem; 2010 Aug; 53(15):5467-75. PubMed ID: 20684594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of Homoverrucosanoid-Derived Esters and Evaluation as MDR Modulators.
    Schäfer A; Köhler SC; Lohe M; Wiese M; Hiersemann M
    J Org Chem; 2017 Oct; 82(19):10504-10522. PubMed ID: 28949536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 4,5-Di-substituted benzyl-imidazol-2-substituted amines as the structure template for the design and synthesis of reversal agents against P-gp-mediated multidrug resistance breast cancer cells.
    Zhang N; Zhang Z; Wong IL; Wan S; Chow LM; Jiang T
    Eur J Med Chem; 2014 Aug; 83():74-83. PubMed ID: 24952376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
    To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
    J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterocyclic cyclohexanone monocarbonyl analogs of curcumin can inhibit the activity of ATP-binding cassette transporters in cancer multidrug resistance.
    Revalde JL; Li Y; Hawkins BC; Rosengren RJ; Paxton JW
    Biochem Pharmacol; 2015 Feb; 93(3):305-17. PubMed ID: 25543853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tetrazole and oxadiazole derivatives as bioisosteres of tariquidar and elacridar: New potent P-gp modulators acting as MDR reversers.
    Braconi L; Dei S; Contino M; Riganti C; Bartolucci G; Manetti D; Romanelli MN; Perrone MG; Colabufo NA; Guglielmo S; Teodori E
    Eur J Med Chem; 2023 Nov; 259():115716. PubMed ID: 37573829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, biological evaluation, molecular docking and QSAR studies of 2,4-dimethylacridones as anticancer agents.
    Murahari M; Kharkar PS; Lonikar N; Mayur YC
    Eur J Med Chem; 2017 Apr; 130():154-170. PubMed ID: 28246041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
    Zhang L; Chen F; Zhang Z; Chen Y; Wang J
    Bioorg Med Chem Lett; 2016 Jan; 26(1):38-42. PubMed ID: 26615886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.
    Gujarati NA; Zeng L; Gupta P; Chen ZS; Korlipara VL
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4698-4704. PubMed ID: 28916341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
    Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery to solve multidrug resistance: Design, synthesis, and biological evaluation of novel agents.
    Qiu Q; Shi W; Zhao S; Zhu Y; Ding Z; Zhou S; Kairuki M; Huang W; Qian H
    Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900127. PubMed ID: 31441108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents.
    Ojima I; Borella CP; Wu X; Bounaud PY; Oderda CF; Sturm M; Miller ML; Chakravarty S; Chen J; Huang Q; Pera P; Brooks TA; Baer MR; Bernacki RJ
    J Med Chem; 2005 Mar; 48(6):2218-28. PubMed ID: 15771464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.